Cellular and molecular pharmacology of antiestrogen action and resistance

Robert Clarke, Fabio Leonessa, James N. Welch, Todd Skaar

Research output: Contribution to journalArticle

332 Citations (Scopus)

Abstract

Antiestrogen therapy remains one of the most widely used and effective treatments for the management of endocrine responsive breast cancers. This reflects the ability of antiestrogens to compete with estrogens for binding to estrogen receptors. Whereas response rates of up to 70% are reported in patients with tumors expressing estrogen and progesterone receptors, most responsive tumors will eventually acquire resistance. The most important factor in de novo resistance is lack of expression of these receptors. However, the mechanisms driving resistance in tumors that express estrogen and/or progesterone receptors are unclear. A tamoxifen-stimulated phenotype has been described, but seems to occur only in a minority of patients. Most tumors (>80%) may become resistant through other, less well defined, resistance mechanisms. These may be multifactorial, including changes in immunity, host endocrinology, and drug pharmacokinetics. Significant changes within the tumor cells may also occur, including alterations in the ratio of the estrogen receptor α:β forms and/or other changes in estrogen receptor-driven transcription complex function. These may lead to perturbations in the gene network signaling downstream of estrogen receptors. Cells may also alter paracrine and autocrine growth factor interactions, potentially producing a ligand-independent activation of estrogen receptors by mitogen-activated protein kinases. Antiestrogens can affect the function of intracellular proteins and signaling that may, or may not, involve estrogen receptor-mediated events. These include changes in oxidative stress responses, specific protein kinase C isoform activation, calmodulin function, and cell membrane structure/function.

Original languageEnglish (US)
Pages (from-to)25-71
Number of pages47
JournalPharmacological Reviews
Volume53
Issue number1
StatePublished - 2001
Externally publishedYes

Fingerprint

Estrogen Receptor Modulators
Estrogen Receptors
Pharmacology
Progesterone Receptors
Neoplasms
Intracellular Signaling Peptides and Proteins
Cell Membrane Structures
Gene Regulatory Networks
Endocrinology
Tamoxifen
Calmodulin
Mitogen-Activated Protein Kinases
Protein Kinase C
Immunity
Intercellular Signaling Peptides and Proteins
Protein Isoforms
Estrogens
Oxidative Stress
Pharmacokinetics
Breast Neoplasms

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cellular and molecular pharmacology of antiestrogen action and resistance. / Clarke, Robert; Leonessa, Fabio; Welch, James N.; Skaar, Todd.

In: Pharmacological Reviews, Vol. 53, No. 1, 2001, p. 25-71.

Research output: Contribution to journalArticle

Clarke, R, Leonessa, F, Welch, JN & Skaar, T 2001, 'Cellular and molecular pharmacology of antiestrogen action and resistance', Pharmacological Reviews, vol. 53, no. 1, pp. 25-71.
Clarke, Robert ; Leonessa, Fabio ; Welch, James N. ; Skaar, Todd. / Cellular and molecular pharmacology of antiestrogen action and resistance. In: Pharmacological Reviews. 2001 ; Vol. 53, No. 1. pp. 25-71.
@article{3100159efd024d4a9cf4848b4b6285e0,
title = "Cellular and molecular pharmacology of antiestrogen action and resistance",
abstract = "Antiestrogen therapy remains one of the most widely used and effective treatments for the management of endocrine responsive breast cancers. This reflects the ability of antiestrogens to compete with estrogens for binding to estrogen receptors. Whereas response rates of up to 70{\%} are reported in patients with tumors expressing estrogen and progesterone receptors, most responsive tumors will eventually acquire resistance. The most important factor in de novo resistance is lack of expression of these receptors. However, the mechanisms driving resistance in tumors that express estrogen and/or progesterone receptors are unclear. A tamoxifen-stimulated phenotype has been described, but seems to occur only in a minority of patients. Most tumors (>80{\%}) may become resistant through other, less well defined, resistance mechanisms. These may be multifactorial, including changes in immunity, host endocrinology, and drug pharmacokinetics. Significant changes within the tumor cells may also occur, including alterations in the ratio of the estrogen receptor α:β forms and/or other changes in estrogen receptor-driven transcription complex function. These may lead to perturbations in the gene network signaling downstream of estrogen receptors. Cells may also alter paracrine and autocrine growth factor interactions, potentially producing a ligand-independent activation of estrogen receptors by mitogen-activated protein kinases. Antiestrogens can affect the function of intracellular proteins and signaling that may, or may not, involve estrogen receptor-mediated events. These include changes in oxidative stress responses, specific protein kinase C isoform activation, calmodulin function, and cell membrane structure/function.",
author = "Robert Clarke and Fabio Leonessa and Welch, {James N.} and Todd Skaar",
year = "2001",
language = "English (US)",
volume = "53",
pages = "25--71",
journal = "Pharmacological Reviews",
issn = "0031-6997",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Cellular and molecular pharmacology of antiestrogen action and resistance

AU - Clarke, Robert

AU - Leonessa, Fabio

AU - Welch, James N.

AU - Skaar, Todd

PY - 2001

Y1 - 2001

N2 - Antiestrogen therapy remains one of the most widely used and effective treatments for the management of endocrine responsive breast cancers. This reflects the ability of antiestrogens to compete with estrogens for binding to estrogen receptors. Whereas response rates of up to 70% are reported in patients with tumors expressing estrogen and progesterone receptors, most responsive tumors will eventually acquire resistance. The most important factor in de novo resistance is lack of expression of these receptors. However, the mechanisms driving resistance in tumors that express estrogen and/or progesterone receptors are unclear. A tamoxifen-stimulated phenotype has been described, but seems to occur only in a minority of patients. Most tumors (>80%) may become resistant through other, less well defined, resistance mechanisms. These may be multifactorial, including changes in immunity, host endocrinology, and drug pharmacokinetics. Significant changes within the tumor cells may also occur, including alterations in the ratio of the estrogen receptor α:β forms and/or other changes in estrogen receptor-driven transcription complex function. These may lead to perturbations in the gene network signaling downstream of estrogen receptors. Cells may also alter paracrine and autocrine growth factor interactions, potentially producing a ligand-independent activation of estrogen receptors by mitogen-activated protein kinases. Antiestrogens can affect the function of intracellular proteins and signaling that may, or may not, involve estrogen receptor-mediated events. These include changes in oxidative stress responses, specific protein kinase C isoform activation, calmodulin function, and cell membrane structure/function.

AB - Antiestrogen therapy remains one of the most widely used and effective treatments for the management of endocrine responsive breast cancers. This reflects the ability of antiestrogens to compete with estrogens for binding to estrogen receptors. Whereas response rates of up to 70% are reported in patients with tumors expressing estrogen and progesterone receptors, most responsive tumors will eventually acquire resistance. The most important factor in de novo resistance is lack of expression of these receptors. However, the mechanisms driving resistance in tumors that express estrogen and/or progesterone receptors are unclear. A tamoxifen-stimulated phenotype has been described, but seems to occur only in a minority of patients. Most tumors (>80%) may become resistant through other, less well defined, resistance mechanisms. These may be multifactorial, including changes in immunity, host endocrinology, and drug pharmacokinetics. Significant changes within the tumor cells may also occur, including alterations in the ratio of the estrogen receptor α:β forms and/or other changes in estrogen receptor-driven transcription complex function. These may lead to perturbations in the gene network signaling downstream of estrogen receptors. Cells may also alter paracrine and autocrine growth factor interactions, potentially producing a ligand-independent activation of estrogen receptors by mitogen-activated protein kinases. Antiestrogens can affect the function of intracellular proteins and signaling that may, or may not, involve estrogen receptor-mediated events. These include changes in oxidative stress responses, specific protein kinase C isoform activation, calmodulin function, and cell membrane structure/function.

UR - http://www.scopus.com/inward/record.url?scp=0035101145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035101145&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 25

EP - 71

JO - Pharmacological Reviews

JF - Pharmacological Reviews

SN - 0031-6997

IS - 1

ER -